Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice

Journal of the American Society of Nephrology

Volumn 14, Issue 10, 2003, Pages 2466-2474

  Bro, Susanne ^a   Bentzon, Jacob F ^b   Falk, Erling ^b   Andersen, Claus B ^a   Olgaard, Klaus ^a   Nielsen, Lars B ^a  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; APOLIPOPROTEIN E; CD11 ANTIGEN; CHOLESTEROL; HOMOCYSTEINE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; MACROPHAGE; MALE; MORTALITY; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UREMIA;

EID: 0141455349     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000088024.72216.2E     Document Type: Article

References (54)

1. Foley RN, Parfrey P, Samak MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32: S112-S119, 1998
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
3. Amann K, Breitbach M, Ritz E, Mall G: Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022, 1998
4. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037-2040, 1998
5. Mall G, Huther W, Schneider J, Lundin P, Ritz E: Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 5: 39-44, 1990
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434-2439, 1999
7. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
8. Ikram H, Lynn KL, Bailey RR, Little PJ: Cardiovascular changes in chronic hemodialysis patients. Kidney Int 24: 371-376, 1983
9. Manske CL, Thomas W, Wang Y, Wilson RF: Screening diabetic transplant candidates for coronary artery disease: Identification of a low risk subgroup. Kidney Int 44: 617-621, 1993
10. Vincenti F, Amend WJ, Abele J, Feduska NJ, Salvatierra O Jr: The role of hypertension in hemodialysis-associated atherosclerosis. Am J Med 68: 363-369, 1980
11. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil III R: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 66: 790-796, 1979
12. Coresh J, Longenecker JC, Miller ER III, Young HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9: S24-S30, 1998
13. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61: 609-614, 2002
14. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
15. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999
16. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
17. Stitt AW, Bucala R, Vlassara H: Atherogenesis and advanced glycation: Promotion, progression, and prevention. Ann N Y Acad Sci 811: 115-127, 1997
18. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71: 343-353, 1992
19. Egrfjord M, Langhoff E, Daugaard H, Olgaard K: Increased clearance rate of prednisone in the isolated perfused liver of uremic rats. Nephron 45: 53-58, 1987
20. Lewin E, Colstrup H, Pless V, Ladefoged J, Olgaard K: A model of reversible uremia employing isogenic kidney transplantation in the rat. Scand J Urol Nephrol 27: 115-120, 1993
21. Krege JH, Hodgin JB, Hagaman JR, Smithies O: A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995
22. Bartels ED, Lauritsen M, Nielsen LB: Hepatic expression of microsomal triglyceride transfer protein and in vivo secretion of triglyceride-rich lipoproteins are increased in obese diabetic mice. Diabetes 51: 1233-1239, 2002
23. Nielsen LB, McCormick SPA, Pierotti V, Tam C, Gunn MD, Shizuya H, Young SG: Human apolipoprotein B transgenic mice generated with 207- and 145-kilobase pair bacterial artificial chromosomes. J Biol Chem 272: 29752-29758, 1997
24. Bentzon JF, Skovenborg E, Hansen C, Moeller J, Saint-Cricq de Gaulejac N, Proch J, Falk E: Red wine does not reduce mature atherosclerosis in apolipoprotein E-deficient mice. Circulation 103: 1681-1687, 2001
25. Nielsen LB, Stender S, Jauhiainen M, Nordestgaard BG: Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with nonlesioned rabbit aorta. J Clin Invest 98: 563-571, 1996
26. Guesdon JL, Terynck T, Avrameas S: The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 27: 1131-1139, 1979
27. Vyberg M, Nielsen S: Dextran polymer conjugate two-step visualization system for immunohistochemistry. A comparison of EnVision+ with two three-step avidin-biotin techniques. Appl Immunohistochem 6: 3-10, 1998
28. Sabattini E, Bisgaard K, Ascani S, Poggi S, Piccioli M, Ceccarelli C, Pieri F, Fraternali-Orcioni G, Pileri SA: The EnVision+ system: A new immunohistochemical method for diagnostics and research. Critical comparison with APAAP, ChemMate. CSA, LABC, and SABC techniques. J Clin Pathol 51: 506-511, 1998
29. Buzello M, Törnig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein E knockout mouse: A model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14: 311-316, 2003
30. Fehrman-Ekholm I, Duner F, Brink B, Tyden G, Elinder CG: No evidence of accelerated loss of kidney function in living kidney donors: Results from a cross-sectional follow-up. Transplantation 72: 444-449, 2001
31. Wen M, Segerer S, Dantas M, Brown PA, Hudkins KL, Goodpaster T, Kirk E, LeBoeuf RC, Alpers CE: Renal injury in apolipoprotein E-deficient mice. Lab Invest 82: 999-1006, 2002
32. Witting PK, Pettersson K, Letters J, Stocker R: Site-specific antiatherogenic effect of probucol in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 20: e26-e33, 2000
33. Schiller NK, Kubo N, Boisvert WA, Curtiss LK: Effect of γ-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21: 1674-1680, 2001
34. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
35. Ejerblad S, Eriksson I, Johansson H: Uraemic arterial disease. Scand J Urol Nephrol 13: 161-169, 1979
36. Tvedegaard E: Arterial disease in chronic renal failure: An experimental study in the rabbit. Acta Pathol Microbiol Immunol Scand 95: 1-28, 1987
37. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
38. Gagnon RF, Gallimore B: Characterization of a mouse model of chronic uremia. Urol Res 16: 119-126, 1988
39. Olgaard K, Finco D, Schwartz J, Arbelaez M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E: Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia. Kidney Int 26: 791-797, 1984
40. Perneger TV, Whelton PK, Klag MJ: History of hypertension in patients treated for end-stage renal disease. J Hypertens 15: 451-456, 1997
41. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, González F, Quiroga T, Caceres MS, Leighton F, Pereira J: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60: 1844-1850, 2001
42. Kren S, Hostetter TH: The course of the remnant kidney model in mice. Kidney Int 56: 333-337, 1999
43. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 57: 401-410, 1991
44. Kasiske BL: Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 32: S142-S156, 1998
45. Drüeke TB, Khoa TN, Massy ZA, Witko-Sarsat V, Lacour B, Descamps-Latscha B: Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int 59: S114-S119, 2001
46. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H: Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci U S A 91: 9441-9445, 1994
47. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R: Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39: 135-141, 2002
48. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM, Koukoudis P, Memmos D: Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: Association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant 17: 435-441, 2002
49. Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M, Moore N, Fillastre JP, Thuillez C: Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 12: 2623-2628, 1997
50. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW: Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia? Kidney Int 54: 1290-1295, 1998
51. Takayama F, Aoyama I, Tsukushi S, Miyazaki T, Miyazaki S, Morita T, Hirasawa Y, Shimokata K, Niwa T: Immunohistochemical detection of imidazolone and N (epsilon)-(carboxymethyl) lysine in aortas of hemodialysis patients. Cell Mol Biol 44: 1101-1109, 1998
52. Greten J, Kreis I, Wiesel K, Stier E, Schmidt AM, Stern DM, Ritz E, Waldherr R, Nawroth PP: Receptors for advanced glycation end-products (AGE): Expression by endothelial cells in non-diabetic uraemic patients. Nephrol Dial Transplant 11: 786-790, 1996
53. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96: 1395-1403, 1995
54. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031, 1998